This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

For Abbott, Diversity Remains Paramount

When it comes to investing in Big Pharma, it's hard to top Abbott (ABT - Get Report), especially as its peers continue to be beaten up.

In short-term, mid-term and long-term assessments of stock performance through Aug. 6, Abbott outpaced its rivals at each measurement most of the time. Abbott has also outperformed the Amex Pharmaceutical Index of big drugmakers at intervals of six months, 12 months, two years and five years.

"Abbott has done well with a diversified platform of nutritional products, diagnostics and devices to help offset the volatility of the pharmaceutical group," says Damien Conover of the financial research firm Morningstar. "Near-term, Abbott is set up for pretty good growth."

Growth was evident in mid-July when Abbott issued second-quarter results that beat Wall Street estimates, raised its full-year earnings forecast and predicted continued double-digit EPS growth in 2009.

Abbott's steady advance over the years has pushed its market capitalization to about $90 billion, trailing only Johnson & Johnson (JNJ - Get Report) and Pfizer (PFE - Get Report) among U.S. Big Pharmas.

Like J&J, Abbott's shares should continue to benefit from diversification, says Catherine Arnold of Credit Suisse, who gave a neutral rating in a recent report.

"We prefer Abbott to J&J in this regard given their relative growth outlook," says Arnold. Her firm has had a recent investment-banking relationship. (Abbott's stock beats J&J at two-year and five-year intervals; J&J wins at six-month and 12-month intervals.)

Arnold is neutral because Abbott is trading near her 12-month target of $59. Morningstar gives Abbott a four-star rating, with five being the highest, saying the stock is just below its fair value forecast of $63. The stock closed at $58.78 on Aug. 6.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ABT $47.68 0.41%
BSX $17.89 -0.50%
GE $26.88 -0.02%
JNJ $100.77 0.19%
MDT $76.54 0.43%

Markets

DOW 18,110.94 +72.97 0.40%
S&P 500 2,113.05 +4.13 0.20%
NASDAQ 5,068.6130 +8.3670 0.17%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs